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Abstract: 
Obesity rates have reached alarming heights globally, having more than doubled since 
the 1980s. Over 60% of diabetic patients are obese, and the increasing severity of the 
disease is associated with Type 2 Diabetes Mellitus (T2DM) incidence, which is 
reversible by weight loss. Understanding the molecular mechanisms linking obesity and 
T2DM could trigger the development of new medication, procedures and perhaps 
devices. 
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor 
expressed in adipose tissue and regulates the expression of genes involved in both 
adipocyte differentiation and lipid metabolism. Another novel transcription factor, Brn-
3b, known to be involved in neuronal development, has recently been shown to be 
expressed in murine adipose tissue and also in peripheral blood cells (PBCs) obtained 
from morbidly obese patients. Furthermore, the expression of Brn-3b was significantly 
reduced in PBCs of diabetic patients.  
The aim of this study was to investigate the expression of PPARγ and Brn-3b in cells of 
the adipose tissue of obese patients undergoing weight-reducing sleeve gastrostomy. 
Anthropometric and biochemical data were collected for all patients. Samples from two 
abdominal adipose tissue depots (subcutaneous and omental) were also obtained from 
each patient. RNA was extracted and qPCR for PPARγ and Brn-3b was performed. 
Our results showed that PPARγ is highly expressed in the adipocytes of omental 
adipose tissue when compared to the adipocytes of the subcutaneous adipose tissue, 
while Brn-3b was not detectable in adipocytes, but exclusive expressed in the stromal 
vascular fraction, especially of the subcutaneous adipose tissue. The expression of Brn-
3b increased with rising levels of systemic insulin and was also elevated in the SVF of 
patients with metabolic disease compared with those without.  
   iv 
In conclusion our study indicated that there was a reciprocal relationship between the 
expression of PPARγ and Brn-3b that needs further investigation, and raises questions 
concerning the implication of Brn-3b in the pathology of obesity and T2DM.
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CHAPTER 1: INTRODUCTION 
  
   2 
Obesity rates have reached alarming rates globally, having more than doubled since the 
1980s. Over 60% of diabetic patients are obese, while increasing severity of obesity is 
associated with disproportionate increase in T2DM incidence and hence, weight loss is 
necessitated. Understanding the molecular mechanisms linking obesity and T2DM could 
trigger the development of new procedures, devices, and medication both for obese and 
non-obese patients.  
Transcription factors are involved in the regulation of expression of multiple genes by 
binding to specific DNA sites of eukaryotic gene promoters. Given their roles as 
modulators of the expression of multiple target genes, they may be of utmost importance in 
the pathways involved in the development of obesity, insulin resistance (IR) and T2DM. 
From the diverse pool of transcription factors, peroxisome proliferator-activator receptor-γ 
(PPARγ) has emerged as potentially important for the pathogenesis of obesity and IR. The 
PPARγ has been implicated in the regulation of lipid and glucose metabolism as well as 
cellular differentiation, especially adipogenesis. PPARγ is expressed in abundance in 
adipose tissue but it is also found in smaller quantities in skeletal muscle and other human 
tissues. It acts as a receptor for endogenous, e.g. fatty acids and prostaglandins, as well as 
exogenous ligands, including thiazolidinediones, a family of pharmacological agents which 
are insulin-sensitizing leading to improved glucose control, reduced inflammation and 
increased adipocyte differentiation. In humans, one study indicated that, compared to 
normal-weight controls, obese subjects who experienced significant weight gain before the 
study exhibited increased PPARγ mRNA levels in PBMC, while no difference was 
observed in other obese groups. As far as expression in whole blood is concerned, one 
study of limited scale has shown that in morbidly obese patients, PPARγ expression 
decreased with increasing Body Mass Index BMI. Investigating PPARγ expression in 
   3 
whole blood appears intriguing because it is easy to obtain and contains peripheral immune 
cells, which are implicated in the pathogenesis of IR. 
POU4F2/Brn-3b (referred to as Brn-3b) belongs to the POU (Pit-Oct-Unc) family of 
nuclear transcription factors. Importantly, Brn-3b has been detected in human PBMC. In 
contrast to the abundance of studies on PPAR-γ, the study of Brn-3b in metabolic diseases 
is novel. A study in morbidly obese patients indicated that Brn-3b expression was 
significantly reduced in whole blood of diabetic versus non-diabetic subjects. These 
findings give rise to questions concerning the implication of Brn-3b in the pathology of 
obesity and T2DM. 
Given the limited amount of data on these two transcription factors in humans, the study of 
differences in their mRNA expression between obese patients, with or without T2DM 
could provide useful information for the etiology of obesity and related co-morbidities. 
In this study we aim to investigate the expression of PPARγ and Brn-3b in relation to 
obesity and surgery-induced weight loss.   
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CHAPTER 2: REVIEW OF THE LITERATURE 
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Obesity: 
 
World health Organization defined obesity as the “abnormal or excessive fat accumulation 
that may impair health” 1. Clinically, obesity is measured by the Body Mass Index (BMI) 
of 30 Kg/m
2
 or greater. BMI is a simple and costless tool that helps in measuring 
underweight, overweight and obesity. It is defined as weight in Kilogram divided by the 
height in meters squared. According to BMI, obesity can be classified into 3 classes: class I 
(BMI: 30- 34.9), class II (BMI: 35- 39.9), and class III (BMI: >40)
 2
.  
Prevalence of obesity: 
The prevalence of obesity has doubled since 1980. The latest statistics from the WHO 
estimate that 11% of adults are obese worldwide
 1
. Qatar is ranked sixth in the Middle East 
for its rate of obesity
 3
.  There is an increase in the mean BMI trends of males from 25.0 to 
28.3 and females from 27.0 to 29.0 through the years 1980 to 2009
 3
.A most recent study 
estimated the prevalence of obesity in Qatar is 40-50%, with greater prevalence in females 
compared to males (54.7% and 44% respectively)
 4
.  
Causes of obesity: 
Obesity is a multifactorial disease, caused by the interaction of several environmental, 
genetics and human behavioral factors. Environmental factors are the main cause of 
obesity when there is excess energy intake compared to low physical activity. Studies 
support the effect of excess energy intake and physical inactivates on obesity. A study 
from England shows that the trend of obesity has increased in parallel with owning a car 
and watching television
 5
. Other environmental factors that show increase in the prevalence 
of obesity are the quality of local parks where it is contribute to physical inactivity
 6
.  
Several studies have demonstrated the association of multiple gene loci with obesity. A 
linkage study done by Hixson and colleague, among Mexican Americans, identified a 
significant association between POMC (Proopiomelanocortin) locus in chromosome 2 and 
variations in the serum leptin levels
 7
. Other linkage studies conducted on Caucasian 
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populations showed the association of obesity with genes on chromosome 3 (e.g. 
adiponectin, GLUT2 and PI3K) and chromosome 17 (e.g. GLUT4 and PPARα) 8. 
Adipose tissue: 
Adipose tissue can be classified according to its anatomical distribution in the body to 
subcutaneous and omental fats. Anatomically subcutaneous adipose tissue is located in the 
mammary and femerogluteal regions, back and abdominal wall. Omental adipose tissue is 
located within the abdominal cavity between the organs. The omental depot contain have 
more inflammatory cells compared to subcutaneous fats 
 9,10
. Normally, fat is accumulated 
in subcutaneous adipose tissue with limited capacity in which if the capacity of fat 
exceeded or impaired, fat will accumulate in areas other than subcutaneous
 11
. Fats are 
abnormally accumulated in omental adipose tissue as results of chronic stress and elevated 
cortisol level
 12
. In a normal lean person, 80% of all body fat is subcutaneous while only 
10-20% is located in omental area 
 13
. 
Adipose tissue composed of adipocytes and stromal vascular fraction (SVF), which contain 
preadipocytes, fibroblasts, vascular cells, neural cells, and immune cells such as adipose 
tissue macrophages. Adipocytes are the main cellular component of adipose tissue and are 
the central store of energy in the form of triglycerides
 11
. When adipocytes continue to 
grow they become larger in size and dysfunctional. These hypertrophied adipocytes are 
insulin resistant and hyperlipolytic. Overall the subcutaneous adipose tissue consists of 
larger adipocytes than those in the omental depot. Paradoxically, the smaller adipocytes of 
the subcutaneous depot are more metabolically active, insulin sensitive and have high 
avidity to uptake free fatty acids and triglycerides
 14,15
. The adipocytes of the omental 
depot, despite being smaller, are more insulin resistant and inflammatory. 
Accumulation of triglycerides in omental adipose tissue is associated with high risk for 
several diseases like hyperglycemia, hyperinsulinemia, and diabetes
 16,17
. In addition to the 
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risk of metabolic syndromes, fat accumulation in the omental area is associated with the 
risk of developing cardiovascular disease and hypertension
10, 18, 19
. 
Transcription factors and its role in obesity: 
PPARγ: 
Peroxisome proliferator-activated receptors (PPARs) members of the nuclear receptor 
(NR) superfamily of ligand activated transcription factors
 20
.  There are three isotypes of 
PPARs: PPARα (NR1C1), PPARβ (NR1C2) and PPARγ (NR1C3) 21,22. Although they are 
encoded by different genes, they share the same molecular structures as most NRs
 23
. 
PPARs are expressed in a variety of body tissues and their location to some extent 
determines their actions. For example, PPARα is highly expressed in liver where it plays 
an important role in regulation of fatty acids metabolism
 24. PPARβ is expressed in all 
body tissues and it is involved in some disorders like cancer, infertility, and dyslipidemia
 
24. PPARγ is expressed at high level in adipose tissue where it regulates adipocyte 
differentiations 
 25,26
. PPARγ-1 and PPARγ-2 are two isoforms of PPARγ 27. They differ in 
the number of amino acid where PPARγ-2 has extra 20 amino acids more that PPARγ-1 28. 
Like other PPARs, PPARγ is composed of an N-Terminal Domain (NTD), DNA Binding 
Domain (DBD) and Ligand Binding Domain (LBD)
 29
 (Figure 1A ).The ligand binding 
pocket for PPARγ is larger when compared to other NRs, allowing it to have a variety of 
ligands 
 30,31. The most common intracellular ligands for PPARγ are polyunsaturated fatty 
acids, such as Linolenic acid and 15-deoxy-delta prostaglandin J2
 32
. Thiazolidinedione’s 
(TZDs) anti-diabetic agents are also found to play a role in activating PPARγ.  
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Figure 1: (A) Molecular structure of PPARγ. (B) Mode of action of PPARγ 
PPARγ form a heterodimer with retinoid X receptor (RXR) that will bind to peroxisome 
proliferator response element (PPRE) in the targeted gene promoter to regulate gene 
expression of several proteins
 29
 (Figure 1B). PPARγ act as transcription factor for several 
proteins that are involved in lipid metabolism, such proteins are adipocyte fatty acid-
binding protein, acyle-CoA synthase, and lipoprotein lipase
 33
. Moreover PPARγ represses 
some genes that are involved in insulin resistance like tumor necrosis factor alpha (TNF-
), leptin, plasminogen activator inhibitor-1, resistin, interleukin-6 (IL-6), and 11-β-
hydroxysteroid dehydrogenase type-1
 34
. 
PPARγ has an important role in lipid storage through induction of adipocyte differentiation 
and fatty acid flux into adipocytes. PPARγ induces the expression of the 
phosphoenolpyruvate carboxykinase ( PEPCK) gene which is a characteristic gene of 
mature adipocyte
 35
. Other studies have shown the effect of PPARγ in differentiation of 
fibroblastic cells into small adipocytes and pre-adipocytes into small adipocytes
 36,37
.  
PPARγ also induce the storage of fatty acid in adipocyte by the activation of lipoprotein 
lipase that stimulate its release from lipoprotein particles
 38
. 
Brn3b: 
Brn-3b is a member of POU family of transcription factors
 39
. POU family of transcription 
factors consists of common domain of highly conserved regions. These regions consist of 
POU-specific domain and the POU homeodomain. Brn-3b is one member of Brn3 group 
that consist of, in addition to Brn-3b, Brn-3a and Brn-3c
 40,41
. Several studies have shown 
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the expression of Brn-3b mRNA in sensory neurons
 40,42,43
, reproductive tissues
 44
 and 
visual system
 45
.  
Recent studies by Hindle et al 
46
 have also shown that Brn-3b is significantly reduced (-
1.68 fold) in blood taken from obese patients with T2D when compared with obese non-
diabetic subjects. Results of preliminary studies have shown that Brn-3b mRNA can be 
measured from RNA extracted from peripheral blood and more importantly, that Brn-3b 
expression is significantly reduced in patients with T2D compared with normal non-
diabetic controls.  
These preliminary findings obtained from analysis of human blood have identified a link 
between reduced Brn-3b and obesity/T2D and has led us to hypothesize that:  
 Loss of Brn-3b in muscle and adipose tissue are associated with obesity and 
deregulation of glucose uptake and metabolism. 
 Increased Brn-3b expression upon weight loss may be important for restoring 
normal metabolic processes. 
In this study we aim to investigate the expression of PPARγ and Brn-3b in adipose tissue 
of obese patients who are scheduled for weight reducing sleeve gastroectomy. Moreover 
we will test the expression of PPARγ and Brn-3b in the different cellular fractions of both 
subcutaneous and omental adipose tissue. The influence of gender and the presence of 
metabolic disease (hypertension and diabetes) on the expression of PPARγ and Brn-3b will 
also be examined.    
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CHAPTER 3: METHODOLOGY 
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Study design: 
A prospective cross-sectional study was conducted on unrelated Arab subjects. Human 
adipose tissue specimens were collected to investigate if the adipose tissue expresses the 
transcriptional factor Bnr-b3 and if it has any relation with the metabolic features of these 
subjects.  
Adipose tissue specimens were collected from morbidly obese patients (BMI ≥40 kg/m2) 
with and without diabetes, dyslipidemia and hypertension (metabolic diseases). All 
patients (males and females) were scheduled for gastric sleeve surgery with energy 
restriction to help reduce their body weight. Obese patients were recruited from metabolic 
surgery unit, Hamad Medical Corporation, from September 2013 to March 2014. All 
subjects who participated in this study signed a consent form in accordance with the 
deceleration of Helsinki 2000, after detailed explanation of the study. Two types of 
abdominal adipose tissue were collected from patients, subcutaneous and omental. 
The patients were classified into two groups based upon their insulin sensitivity: insulin 
resistant and insulin sensitive. . The medical history and medication of the patients were 
recorded as well as fasting HbA1c (%) and serum concentration of glucose, high-density 
lipoprotein (HDL)-cholesterol, and total cholesterol, and insulin. Samples were collected 
during the surgical procedure and immediately transported to the Life Sciences Research 
Division of the Anti-Doping Laboratory Qatar where it was immediately further processed 
by collagenase digestion to isolate the adipocytes and the stromal vascular cells, followed 
by RNA extraction and q-PCR. 
Ethical consideration: 
Ethical approval for the study protocol was obtained from both the Institutional Review 
Boards of Hamad Medical Corporation and Anti-Doping Laboratory Qatar. Confidentiality 
of data was assured by the use of anonymized identity numbers on all data recording 
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forms. The principal investigator holds the link between names and identity numbers in 
forms placed in secured location that satisfies the local requirements for data protection. 
Sample preparation: 
1g of fresh adipose tissue was used to fractionate adipose tissue to its cellular component 
using collagenase enzyme (Gibco, cat. #: 17100-017). 
100ml of Fresh collagenase solution was prepared by mixing 86.67ml of 2mM CaCl2, 
13.3ml of 7.5% BSA and 0.5g of collagenase Type1 from Gibco (cat.#: 17100-017).  
1ml of collagenase per 1g of tissue was added, the tube placed horizontally in a shaking 
water-bath and incubated for 1-hour at 37
◦
C. After incubation, the tubes were centrifuged 
for 5 minutes at 1790 rpm. Then the sample was taken out and shaken vigorously to disrupt 
the pellet and mix the cells. The centrifugation was repeated at 1790 rpm for 5 minutes. 
After centrifugation the samples showed several separated layers: Top oil and fat layer, 
yellow layer of floating adipocyte cells, underlying layer of collagenase solution, and a 
dark red layer of SVF at the bottom of the tube. The oil and collagenase layers were 
discarded and the adipocytes (yellow layer of floating cells) were carefully transferred to a 
new tube and taken for RNA isolation. 
10ml of prewarmed PBS with 1%BSA was added to the remaining SVF layer and 
transferred to a new tube and centrifuged at 1790 rpm for 5 minute. Any remaining 
collagenase and oil, if present, was removed. 3ml of Erythrocyte lysis buffer was then 
added and incubated for 10 minutes at room temperature. After incubation, the sample was 
centrifuged at 1790 rpm for 5 minute and the lysis buffer removed before proceeding to 
RNA isolation. 
RNA extraction: 
RNA extraction was performed using Trizol reagent (Invitrogen cat. #: 15596-026) as 
described in the manual. 
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1ml of TRIzol per 50-100mg of tissue sample was added and pipetted up and down several 
times to lyse the cells and then incubated for 5 minutes at room temperature. Chloroform 
(0.2ml chloroform per 1ml Trizol) was added, vortexed vigorously for 15 second and then 
centrifuged at 14000 rpm for 15 minute at 4 
◦
C. After centrifugation the aqueous phase was 
collected into a new tube and 0.5ml of 100% Isopropanol added to precipitate the nucleic 
acids. The sample was incubated at -20 for at least 1 hour or overnight, followed by 
centrifugation at 14,000 rpm for 15 minutes at 4
◦
C. After centrifugation the isopropanol 
was removed very carefully leaving the RNA pellet. The RNA pellet was washed twice 
with 1ml of 75% ethanol per 1ml Trizol and centrifuged at 14,000 rpm for 5 minutes at 4 
◦
C. After the last wash, the ethanol was removed carefully from tube and the pellet allowed 
to air dry on ice with for 10 minutes. The pellet was resuspended in 30μl of RNase free 
water and incubated at 56
◦
C for 10 minute. The sample was left on ice for a further 10 
minutes before being stored at -80
◦
C. 
Measuring Quality and Quantity of RNA: 
The RNA was quantified by measuring the A260/A280 ratio using the NanoDrop ND-
1000 V3.7.1 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware, USA). 
The Nucleic Acid Bio-analyzer 2100 (Agilent) was used to determine the quality of the 
RNA.  
cDNA synthesis: 
cDNA was synthesized by taking 200ng of RNA using High Capacity cDNA Reverse 
Transcription Kit (life technology, Cat.#4369914). The following reaction volumes were 
used for cDNA synthesis: 
Component Volume/Reaction (µL)  
10x RT Buffer 2.0  2 
25✕xdNTP Mix (100 mM)  0.8 
10x RT Random Primers  2 
MultiScribe™ Reverse Transcriptase 1 
Nuclease-free H2O 4.2 
Total per Reaction  10 
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10 µL of 200ng RNA was added to the above reaction mix and reverse transcriptase 
performed in the thermal cycler. The RT enzyme is activated by incubation at 25
◦
C for 15 
minute followed by transcription at 37
◦
C for 2 hours, with a final inactivation step at 85
◦
C 
for 5 minute. The newly synthesized cDNA was stored at -20 °C for RT-qPCR. 
RT-qPCR:  
The relative quantitation of gene expression was performed using real-time polymerase 
chain reaction (RT-PCR). Taqman probes for β-actin (Cat. #: Hs99999903), PPARγ (Cat. 
#: Hs01115513) and Brn-3b (Cat. #: Hs00960964) genes were ordered from Applied 
Biosystem with amplicons length of 171bp, 90bp and 51bp respectively. 
PCR was performed by adding 10μl TaqMan Gene Expression Master Mix (Applied 
Biosystems, Cat. #: 436901), 1μl TaqMan probe, 1 μl cDNA and 8μl RNAse-free water to 
make total volume of 20μl. Reaction mix was run on the ViiA™ 7 Real-Time PCR System 
(Applied Biosystems) according to the manufacture protocol. 
Data analysis: 
Cycle threshold (Ct) is defined as the cycle number at which a significant increase in the 
fluorescence signal compared to background emission is first detected. Calculating Ct 
values for each sample was performed to quantify unknown samples. ΔCt was defined for 
each sample by subtracting the β-actin gene Ct from each selected gene Ct. Relative gene 
expression was calculated by the 2
-ΔΔCt
 method, i.e. the negative exponential power of 2 of 
each sample’s ΔCt minus the ΔCt of a reference sample, which kept constant throughout 
the experiments. 
Statistical Analysis: 
The results are expressed as mean ± SD for all normally distributed data or as median 
(interquartile ranges) for non-parametric values. Differences among experimental groups 
were evaluated by Mann-Whitney U test for non-normally distributed data. Spearman 
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Rank correlation was used to evaluate the relationship between BMI and gene expression 
of our study subjects as the data was skewed. The figures show Pearson Correlation data as 
the non-parametric results could not be plotted as a graph to show the direction ofg the 
relationship, while the strength of the relationship is hsown using Spearman Rank r values. 
Significance was defined as two-tailed P <0.05. All statistical analyses were performed 
using the SPSS program for Windows (version 21 statistical software; Texas instruments, 
IL, USA). 
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Patient’s Demographic data: 
 
The clinical data and biological parameters of the patients recruited in the study are 
summarized in Table 1. The clinical data includes medical history of the patients, systolic, 
diastolic and mean arterial blood pressure (SBP, DBP and MAP), and systemic glucose 
and insulin levels. All patients were obese with an average age of 42 years old and BMI of 
45.9 Kg/m
2
. According to the clinical data, patients were classified into 2 groups: 
Metabolically Healthy Obese (MHO) and Pathological Obese. MHO were characterized by 
fasting plasma glucose (FPG) < 7.8 mmol/L, insulin level < 6.5 miU/mL, SBP<140 
mmHg, DBP<85 mmHg and have no metabolic diseases. The other group, PO, were 
characterized by having FPG <7.8 mmol/mL, insulin level > 7.0 miU/mL with or without 
any metabolic diseases. Of the 9 patients, 3 patients were classified as MHO therefore they 
are used as a control in this study. 
Table 1: Clinical data and biological parameter of the patients: 
Sample 
Number 
Gender History Age 
Weight 
(kg) 
BMI SBP DBP MAP Glucose Insulin 
MHO/
PO 
1 F No history 34 128 53 110 80 90 6.8 13.75 PO 
2 
M 
Hypertensio
n 40 124 40.5 130 70 90 5.5 16.85 PO 
3 
F 
Diabetes & 
Hypertensio
n 41 128 39.5 132 70 90.7 4.9 11.31 PO 
4 F No history 51 112 48 168 94 118.7 7.1 11.34 PO 
5 
M 
Hypertensio
n 46 118 40.8 140 70 93.3 4.4 27.21 PO 
6 M Diabetes 17 98 36.4 130 6.8 98 6.9 8 PO 
7: 
Control F No history 42 98.5 46.5 120 74 89.3 6.2 4.25 MHO 
8: 
Control F No history 39 98 41 130 80 96.7 5.4 4.65 MHO 
9: 
Control M No history 29 157 40 130 80 96.7 12.8 5.62 MHO 
Adipose Tissue treatment and RNA extraction: 
 
Subcutaneous and omental adipose tissues were collected from patients at the time of the 
operation. Collagenase digestion separates the adipose tissue to its cellular components: 
stromal vascular fraction (SVF) and adipocytes (ADIPO). Each patient, therefore, had 4 
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samples:  SC-SVF, SC-ADIPO, OM-SVF and OM-ADIPO. Table 2 shows concentrations 
of RNA for each sample and Figure 2 shows the results of bio-analyzer for checking the 
quality of the isolated RNA. RNA with poor quality (Figure 2 -b) was excluded from the 
analysis as they may interfere with accuracy of the results.  
Table 2: List of RNA concentrations: 
Sample 
Number 
Adipose tissue 
fraction 
Concentrations 
(ng/μl) 
Sample 
Number 
Adipose 
tissue fraction 
Concentrations 
(ng/μl) 
1 
SVF-SC 19.7 
5 
SVF-SC 153.1 
SVF-OM 44 SVF-OM 127 
ADIPO-SC 33.6 ADIPO-SC 73.3 
ADIPO-OM 61.7 ADIPO-OM 141.9 
2 
SVF-SC 84.3 
6 
SVF-SC 85.1 
SVF-OM 53.2 SVF-OM 257.6 
ADIPO-SC 220.9 ADIPO-SC 333.7 
ADIPO-OM 163.3 ADIPO-OM 474.6 
3 
SVF-SC 139.2 
7 
SVF-SC 91.2 
SVF-OM 210.9 SVF-OM 78.5 
ADIPO-SC 191.6 ADIPO-SC 83.8 
ADIPO-OM 3048.7 ADIPO-OM 43 
4 
SVF-SC 83.3 
8 
SVF-SC 95.6 
SVF-OM 66.8 SVF-OM 325.4 
ADIPO-SC 77.2 ADIPO-SC 227.7 
ADIPO-OM 78.5 ADIPO-OM 188.4 
Control 
SVF-SC 191.3 Abbreviation:  
SVF: Stromal Vascular Fractions, ADIPO: 
Adipocyte, OM: Omental, SC: Subcutaneous 
SVF-OM 28.2 
ADIPO-SC 47.5 
ADIPO-OM 66.1 
      Figure 2: Comparison between good (a) and poor (b) quality of RNA 
Gene expression: 
PPARγ: 
Results of PPARγ expression for individual patients are shown in Figure 3. As can be seen 
the data are skewed and the median (and interquartile range) of mRNA expression of 
PPARγ is shown in Figure 4. PPARγ was expressed in both subcutaneous and omental 
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adipose tissue. Compared to SVF, adipocytes showed significantly higher expression of 
PPARγ in tissues from both depots (sc: p=0.025; om p=0.05; Figure 5 A and B). Further, 
unlike in adipocytes, the SVF expression of PPARγ was significantly higher in cells of the 
subcutaneous adipose tissue than in omental adipose tissue (p=0.042).  
 
Figure 3: mRNA expression of PPARγ for each patient. 
Data are shown as mean (± SD). SVF: Stromal Vascular Fractions, ADIPO: Adipocyte, OM: Omental, SC: 
Subcutaneous 
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Figure 4: mRNA expression of PPARγ. 
Data are shown as median (±Interquartile range). SVF: Stromal Vascular Fractions, ADIPO: Adipocyte, OM: 
Omental, SC: Subcutaneous.  
Figure 5: Comparison of PPARγ expression in (A) subcutaneous and (B) omental adipose tissue. 
Data are shown as mean. SVF: Stromal Vascular Fractions, ADIPO: Adipocyte,  
 
Mediators of PPAR expression: 
Figure 6 and 7 shows positive Pearson correlations between PPARγ expressions in 
adipocyte of subcutaneous and omental tissues and BMI of the patients (Spearman Rank 
correlations: SC: r=0.80, p= 0.01 & OM: r=0.52, p=0.15). Thus, as BMI increased so did 
the expression of PPARγ in adipocytes of the subcutaneous and in the omental depots. 
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There was also significantly higher expression of PPARγ in the adipocytes of the 
subcutaneous depot of females compared to males (Figure 8).  
Figure 6: Pearson Correlation between BMI and the expression of PPARγ in adipocytes of omental 
adipose tissue  
Figure 7: Pearson Correlation between BMI and the expression of PPARγ in adipocytes of 
subcutaneous adipose tissue. 
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Figure 8: mRNA expression of PPARγ in male and female. 
Data are shown as mean (± SD). SVF: Stromal Vascular Fractions, ADIPO: Adipocyte, OM: Omental, SC: 
Subcutaneous. Comparisons are Mann-Whitney U p-values and significance at <0.05 is shown by *. 
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Brn-3b: 
Expression of Brn-3b of all patients is shown in Figure 9. Figure 10 shows the median (and 
interquartile range) of mRNA expression of Brn-3b. Brn-3b was expressed in the SVF of 
both subcutaneous and omental adipose tissue (P=0.007), while expression was not 
detected in the adipocytes of either adipose tissue depot.  
Figure 9: mRNA expression of Brn-3b for each patient: Data are shown as mean (± SD). SVF: Stromal 
Vascular Fractions, ADIPO: Adipocyte, OM: Omental, SC: Subcutaneous. 
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Figure 10: mRNA expression of Brn-3b: Data are shown as median (±Interquartile range). SVF: Stromal 
Vascular Fractions, ADIPO: Adipocyte, OM: Omental, SC: Subcutaneous. p values significance at <0.05 is 
shown by * 
 
Mediators of Brn-3b: 
Figure 11 shows positive correlation between insulin level and expression of Brn-3b in the 
SVF of subcutaneous adipose tissue.  
 
Figure 11: Corrolation between insulin level and the expression of Brn-3b in SVF of subcutaneus 
adipose tissue. 
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Brn-3b vs. PPAR: 
Interestingly there were negative associations between the expression of Brn-3b and 
PPARFigure12)Table 3 shows Pearson rank correlation and Figure 13 shows Pearson 
correlations between both transcription factors.  
 
Table 3: Spearman Rank correlation between PPARand Brn-3b expression in subcutaneous and 
omental adipose tissue. 
 Brn-3b-SVF-SC Brn-3b-SVF-OM 
PPAR-SVF-SC 
R= - 0.898 R= - 0.728 
P= 0.001 P= 0.026 
PPAR-ADIP-SC 
R= - 0.712 R= - 0.703 
P= 0.031 P= 0.035 
 
 
 
 
Figure 12: mRNA expression of PPARγ and Brn-3b in subcutaneous and omental adipose tissue. 
Data are shown as mean (± SD). SVF: Stromal Vascular Fractions, ADIPO: Adipocyte, OM: Omental, SC: 
Subcutaneous. Comparisons are Mann-Whitney U and p values, significance at <0.05 is shown by *  
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Figure 13: Pearson correlations between PPARand Brn-3b expression in subcutaneous and omental 
adipose tissue 
 
PPAR, Brn-3b and metabolic disease: 
PPAR expression was significantly elevated in both the adipocytes (p=0.016) and in the 
SVF (p=0.016) of the sub-cutaneous depots of the patients without any history of 
metabolic disease (no diabetes or hypertension). 
Conversely, Brn-3b expression was elevated in the SVF of both the subcutaneous 
(p=0.032) and the omental (p=0.063) tissue of the patients with metabolic disease, 
compared to those without. 
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CHAPTER 5: DISCUSSION 
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The global increase in the rate of obesity and its associated comorbidities has led 
researchers to try and understand the molecular mechanisms that underlie the relationship 
between obesity and disease. Several transcription factors are known to play a role in 
obesity. Peroxisome proliferator-activated receptor gamma (PPARγ) is an example of one 
of these transcription factors. This transcription factor plays a major role in the regulation 
of both adipocyte differentiation and metabolism. Furthermore, synthetic ligands of 
PPAR the thiazolidinedione family of compounds are already used as therapeutic agents 
in diabetes and obesity.  
An unpublished study of obese patients showed that expression of another transcription 
factor, Brn-3b, was significantly reduced in whole blood of diabetic patients. The role of 
this factor in obesity and diabetes, as well as in the adipose tissue, is all, as yet, 
unexplored. 
The aim of this study was, firstly, to ascertain the expression of PPARγ and Brn-3b in 
subcutaneous and omental adipose tissue of obese patient undergoing weight-reducing 
sleeve gastroectomy. Furthermore, the expression of PPARγ and Brn-3b was also 
determined in the different cellular fractions, adipocytes and the SVF, of both 
subcutaneous and omental adipose tissue. Lastly, interactions between the expression of 
the two transcription factors themselves, as well as with other mediators, such as gender, 
body mass and the presence of metabolic diseases were investigated.  
We found that PPARγ is expressed in the adipocytes of both subcutaneous and omental 
adipose tissue. This result is consistent with the literature where it has been shown that 
PPARγ is highly expressed in adipose tissue and is a key regulator of differentiation of 
preadipocytes to mature adipocyte.
 25,26
 The stromal vascular fractions (SVF) showed 
lower expression of PPARγ compared to that in adipocytes. The SVF consists of 
preadipocytes, fibroblasts, vascular cells, neuronal cells, and immune cells such as adipose 
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tissue macrophages. The low expression of PPARγ in SVF probably reflects lower 
expression in preadipocytes compared to adipocytes, as only on the onset of adipogenesis 
is there an increase in PPARγ which is responsible for the events leading to the cellular 
growth arrest prior to differentiation into adipocytes, as well as the induction of adipocyte 
specific genes
 47
. As these preadipocytes within the SVF are derived from adult humans, 
especially those with morbid obesity, it may also reflect their lower capacity to expand this 
adipose tissue depot. Another possible explanation is that this expression of PPARγ is due 
to adipocytes contaminating the SVF fraction. This is one limitation of the study that could 
have been controlled for by screening for adipocyte markers, such as adiponectin or 
adipsin. In keeping with data showing that females have more subcutaneous adipose tissue 
than males
 48
, we found that PPARγ expression in adipocytes of subcutaneous adipose 
tissue of females was higher than that of males (p=0.027). Our data also showed a positive 
correlation between BMI and PPARγ expression in the adipocytes of the subcutaneous 
adipose tissue. Both these confirm findings for PPAR expression in cells of the adipose 
tissue from previous studies and act as an ample control for our findings with Brn-3b.  
This study is the first that has investigated the expression of Brn-3b in human adipose 
tissue. We found that Brn-3b is significantly expressed in SVF cells of subcutaneous 
adipose tissue compared to omental adipose tissue. There was little or no expression of 
Brn-3b in adipocytes, either because it is not expressed in adipocytes or it is shut down 
during adipogenesis. We found a significant correlation between Brn-3b and insulin levels, 
where the expression of Brn-3b in SVF especially of the subcutaneous adipose tissue is 
increased with the rising systemic insulin level. This suggests that a hyperinsulinaemic 
state is likely to be marked by elevated expression of Brn-3b. In keeping with this we 
found that while PPAR expression was significantly elevated in both the adipocytes and 
in the SVF of the sub-cutaneous depots of the patients without any history of metabolic 
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disease (no diabetes or hypertension), Brn-3b expression was elevated in the SVF of both 
the subcutaneous and the omental tissue of the patients with metabolic disease, compared 
to those without. Patients with metabolic disease are often hyperinsulinaemic. We also 
found significant inverse relationships between adipocyte PPARand SVF Brn-3b of both 
adipose tissue depots.  This relationship needs further investigation, and it also raises 
questions concerning the implication and the role of Brn-3b in the pathology of obesity and 
T2DM.  
In other data from our group it was found that murine preadipocytes and adipocytes do not 
express Brn-3b. If this is confirmed in humans, and this current data points to that, then 
other cells within the SVF, such as smooth muscle cells, endothelial cells and/or neuronal 
cells are likely to be the major cells that express this transcription factor. The depot 
specific difference seen here would then reside within changes in these cells depending on 
the depot from which they derive.  
Obesity and T2DM pose a serious threat to human health, but the molecular mechanisms 
that predispose to this disease are not understood. Our data supporting the role for Brn-3b 
in obesity and hyperinsulinaemia, both linked with increased risk for T2DM may have 
implications for human health and must be investigated further. Whether we can readily 
measure Brn-3b in peripheral blood is yet to be ascertained. If this were to confirm our 
results in the SVF this would be a significant advantage because blood samples are more 
readily accessible for analysis than biopsies from metabolically active tissues such as 
muscle, adipose tissue or liver. By measuring Brn-3b levels in pre-and post-surgery blood 
samples from a larger number of patients, we could assess how altered expression 
correlates with weight loss/BMI as well as clinical parameters such as weight, fasting 
plasma glucose, insulin and HOMA-IR (index of insulin resistance). We could also 
determine whether such levels are affected by age. 
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Furthermore, there is a Brn-3b knockout mouse model that is available and will be useful 
in determining whether intake of high fat can affect the expression of Brn-3b and how this 
correlates with weight gain and metabolic dysfunction. This model can also be helpful to 
test if weight-loss is associated with reversal of Brn-3b expression which is important if 
loss of Brn-3b turns out to be important for weight gain and development of T2DM. The 
Brn-3b KO mutant studies will provide a good model to determine how loss of Brn-3b 
affect gene expression changes linked to weight gain and metabolic dysfunction. 
Furthermore this model will be invaluable for identifying potential Brn-3b target genes in 
metabolically active tissue so that we can determine how this regulator controls normal 
glucose uptake/metabolism. 
In conclusion our study indicated that there was a reciprocal relationship between the 
expression of PPARγ and Brn-3b that needs further investigation, and raises questions 
concerning the implication of Brn-3b in the pathology of obesity and T2DM. 
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